375 related articles for article (PubMed ID: 32139179)
1. Recent insights into the biology of pancreatic cancer.
Yao W; Maitra A; Ying H
EBioMedicine; 2020 Mar; 53():102655. PubMed ID: 32139179
[TBL] [Abstract][Full Text] [Related]
2. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives.
Wang S; Zheng Y; Yang F; Zhu L; Zhu XQ; Wang ZF; Wu XL; Zhou CH; Yan JY; Hu BY; Kong B; Fu DL; Bruns C; Zhao Y; Qin LX; Dong QZ
Signal Transduct Target Ther; 2021 Jul; 6(1):249. PubMed ID: 34219130
[TBL] [Abstract][Full Text] [Related]
3. The roles of intratumour heterogeneity in the biology and treatment of pancreatic ductal adenocarcinoma.
Evan T; Wang VM; Behrens A
Oncogene; 2022 Oct; 41(42):4686-4695. PubMed ID: 36088504
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic.
Fokas E; O'Neill E; Gordon-Weeks A; Mukherjee S; McKenna WG; Muschel RJ
Biochim Biophys Acta; 2015 Jan; 1855(1):61-82. PubMed ID: 25489989
[TBL] [Abstract][Full Text] [Related]
5. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions.
Lin W; Noel P; Borazanci EH; Lee J; Amini A; Han IW; Heo JS; Jameson GS; Fraser C; Steinbach M; Woo Y; Fong Y; Cridebring D; Von Hoff DD; Park JO; Han H
Genome Med; 2020 Sep; 12(1):80. PubMed ID: 32988401
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
8. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.
Balachandran VP; Beatty GL; Dougan SK
Gastroenterology; 2019 May; 156(7):2056-2072. PubMed ID: 30660727
[TBL] [Abstract][Full Text] [Related]
9. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
[TBL] [Abstract][Full Text] [Related]
10. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
11. Tumor heterogeneity: An oncogenic driver of PDAC progression and therapy resistance under stress conditions.
Palma AM; Vudatha V; Peixoto ML; Madan E
Adv Cancer Res; 2023; 159():203-249. PubMed ID: 37268397
[TBL] [Abstract][Full Text] [Related]
12. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic approach for advanced pancreatic adenocarcinoma.
Kaur J; Mir T; Gill R; Duong J; Marcus S; Khan R
Immunotherapy; 2021 Jun; 13(9):767-782. PubMed ID: 33910383
[TBL] [Abstract][Full Text] [Related]
14. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM
J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
Sahin IH; Askan G; Hu ZI; O'Reilly EM
Ann Oncol; 2017 Dec; 28(12):2950-2961. PubMed ID: 28945842
[TBL] [Abstract][Full Text] [Related]
16. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
Fu Y; Liu S; Zeng S; Shen H
Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
[TBL] [Abstract][Full Text] [Related]
17. [Advances in immunotherapy of pancreatic ductal adenocarcinoma].
Yang JQ; Wei T; Chen YW; Bai XL; Liang TB
Zhonghua Wai Ke Za Zhi; 2017 May; 55(5):396-400. PubMed ID: 28464583
[TBL] [Abstract][Full Text] [Related]
18. The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions.
Herting CJ; Karpovsky I; Lesinski GB
Cancer Metastasis Rev; 2021 Sep; 40(3):675-689. PubMed ID: 34591240
[TBL] [Abstract][Full Text] [Related]
19. Role of epigenetics in pancreatic ductal adenocarcinoma.
Pandey S; Gupta VK; Lavania SP
Epigenomics; 2023 Jan; 15(2):89-110. PubMed ID: 36647796
[TBL] [Abstract][Full Text] [Related]
20. Modeling pancreatic cancer in mice for experimental therapeutics.
Mallya K; Gautam SK; Aithal A; Batra SK; Jain M
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188554. PubMed ID: 33945847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]